You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD

    SBC: RIP ROAD, INC.            Topic: NIA

    Project SummaryImpairment in instrumental activities of daily living (IADL) is a hallmark of Alzheimer’s disease (AD) dementia and a major source of patient and caregiver burden. Similarly to cognitive changes in AD, subtle difficulties in IADL may begin even before the stage of amnestic mild cognitive impairment (MCI). Recently, greater emphasis has been placed on preclinical AD, which consists ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Programming Metabolically Fit TILs for Immunotherapy

    SBC: LIPO-IMMUNO TECH LLC            Topic: NCI

    ABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL

    SBC: Actinium Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Despite treatment advances, the prognosis of adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and R/R diffuse large B-cell lymphoma (DLBCL) remains poor. Autologous T- cells modified to express a CD19-targeted chimeric antigen receptor (CAR T-cells) produce durable responses in subgroups of these patients, which has led to FDA approval of two su ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum

    SBC: STEM CULTURES LLC            Topic: 400

    Scientific Abstract: The frequent use of fetal bovine serum (FBS) to support cell cultures is challenged by lot-to-lot variability, supply constraints, pathogen contaminants and ethical questions. These issues have increased significance due to the burgeoning use of FBS in cell research and therapy development. FBS has been used for over a century to culture cells, but with the need to define cult ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Remedy for Periodontal Bone Loss

    SBC: PERIOMICS CARE LLC            Topic: NIDCR

    Periodontitis is a common chronic inflammatory disease characterized by destruction of the supporting structures of the teeth (the periodontal ligament and alveolar bone). The total prevalence of periodontitis in adults aged 30 years and older was 47.2% (representing about 64.7 million adults aged 30 years and older) and 70.1% in adults aged 65 years and older in the U.S. The current treatment opt ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin

    SBC: POP Biotechnologies Inc.            Topic: NCI

    Summary Our goal is to commercialize interstitial chemo-phototherapy (I-CPT) as a new therapeutic option for locally advanced liver cancers. Doxorubicin (Dox) can be actively loaded into long circulating, serum-stable, porphyrin- phospholipid (PoP) liposomes and be released with 665-nm laser light (PhotoDox). This approach leads to vastly enhanced drug accumulation in irradiated tissues, resulting ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Affordable sialoglycans and associated reagents for expanded chemoenzymatic production

    SBC: Integrated Micro-Chromatography Systems, Inc.            Topic: 300

    Project Summary Sialoglycans are sialic acid-containing oligosaccharides that play important biological roles in human biology and pathology and are indispensable molecular probes for research related to bacterial and viral infection, cancer metastasis, immune regulation, etc. The multifaceted functions of sialoglycans in human milk are also being explored. Nevertheless, sialoglycan-related resear ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Teleconsent: Enabling informed consent for remote care and research

    SBC: Doxy.me Inc.            Topic: 100

    PROJECT SUMMARY . Informed consent is legal and ethical requirement in health care and research that assures that individuals have the autonomy to make informed care and research decisions at their own volition, under no coercion or undue influence, and with reasonable understanding of the risks, benefits, and responsibilities of their decisions as they would in-person. Obtaining informed consent ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Development of KLS-13019 for Neuropathic Pain

    SBC: KannaLife Sciences Inc.            Topic: 106

    Neuropathic pain remains a challenging neurologic disorder that adversely affects quality of life and presents a large unmet medical need. Chemotherapy-induced peripheral neuropathy (CIPN) is a chronic, severely debilitating consequence of cancer therapy for which there are no effective management strategies. Upwards of 80-97% of CIPN patients reported using prescription opioids for this pain mana ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Mitigating Injurious Falls in Older Adults Through Non-Injurious Fall and Gait Analysis From Floor Vibrations

    SBC: ADVANCED SMART SYSTEMS AND EVALUATION TECHNOLOGIES, LLC            Topic: NIA

    Project Summary and Abstract Falls are the leading cause of death due to injury. Falls are so common that 30% of community dwelling older adults, and 50% of residents in Care Facilities will experience a fall in the coming year. The risk of falling substantially increases for those having Alzheimer’s disease and related dementias. The financial burden is significant with fall-related costs being ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government